cyrilzakka/clinical-trials huggingface dataset:
Usability and Effectiveness of ReHub in Patients After Total Hip Arthroplasty

This is a randomized, non-blinded, parallel assignment, clinical trial for the evaluation of usability and effectiveness of ReHub, a telerehabilitation system made up of a cloud platform and an exercise kit with smart sensors, for performing rehabilitation exercises after a primary Total Hip Arthroplasty (THA).

Patients admitted to Presidio San Camillo after a THA surgery are randomly allocated to the control arm or the experimental arm with a 1:1 ratio. Participants in both arms receive inpatient care and rehabilitation for 2 weeks at San Camillo. At discharge, they are prescribed with the same daily plan of 5 exercises for autonomous home-based rehabilitation. The experimental arm participants use ReHub to do their exercises instead of working independently and physiotherapists monitor their performance and adherence remotely.

Outcomes assessment is performed at San Camillo admission (baseline), at San Camillo discharge (2 weeks from baseline) and 3 weeks after San Camillo discharge (5 weeks from baseline).


Eligibility Criteria:
Inclusion Criteria:

* Ability to understand and accept the clinical study procedure and to sign an informed consent form
* Good familiarity with the Italian language
* Good predisposition to the use of technology or availability of a caregiver providing technological support to the patient
* Availability to move to the Rehabilitation Center for control visits

Exclusion Criteria:

* Age \<60 or \>80 years
* Admission after THA revision surgery
* Contralateral hip osteoarthritis severely limiting patient mobility and ability to comply with a rehabilitation program
* Aphasia, dementia, or psychiatric comorbidity interfering with communication or adherence to the rehabilitation process
* Respiratory, cardiac, metabolic, or other condition limiting patient mobility and ability to comply with a rehabilitation program
* Major medical complications occurring after surgery that prevented the discharge of the patient within 10 days after the surgery
* Body mass index \>35kg/m2
The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.

Preclinical data support the investigation of PARP inhibitors in other neoplasms exhibiting homologous recombination deficiency (HRD) as monotherapy as well as in combination with chemotherapy. However，in colorectal cancer (CRC), the role of HRD alterations is mostly unknown. This study aims to explore the the Efficacy and Safety of Fluzoparib combined with Irinotecan in the Second-line treatment of HRD alterations metastatic colorectal cancer.

Study protocol for an open-label, single-arm, phase II study of combination of Fluzoparib and rinotecan as the second-line treatment for patients with HRD alterations metastatic colorectal cancer (mCRC). Patients will receive Fluzoparib combined with Irinotecan treatment protocol, which included irinotecan asintravenous infusion at 180mg/m2 (on day 1) and Fluzoparib 150mg capsules given bid (days 1-7) every 2 weeks.

Eligibility Criteria:
Inclusion Criteria:

* 18-75 years；
* Histological or cytological confirmed metastatic colorectal cancer;
* HRD alterations（inclued BRCA1/2、ATM、CDK12、PALB2、Check2、RAD51C、RAD51D etc.）；
* Intolerability toxicity occurs 8 weeks within first-line therapy;
* ECOG PS 0-1;
* Adequate hepatic, renal, heart, and hematologic functions;
* Negative serum pregnancy test at screening for women of childbearing potential;
* Informed consent was signed before the study began.

Exclusion Criteria:

* Prior treatment with PARPi drugs；
* Symptomatic brain or meningeal metastases；
* Patients have received local radiotherapy within 1 month prior to treatment;
* Patients who had active bleeding or coagulopathy before enrollment, had a tendency to bleed, or were receiving thrombolytic therapy and were considered by the investigator to be ineligible for enrollment;
* Women who are pregnant (with a positive pregnancy test before medication) or breastfeeding;
* Expected survival \<3 months;
* Received other investigational drugs within 4 weeks prior to treatment;
* Patients who had active uncontrollable neurological, mental disease or mental disorder, poor compliance, unable to cooperate and describe the treatment response;
* Allergy to the study drug or any of its excipients;
The Role of Stress in Self-Control, Coping, and Emotion Regulation

The purpose of this study is to examine the effects of stress on mental and physical health and behavior.


Eligibility Criteria:
Inclusion Criteria:

* ages 18-50
* able to read and write

Exclusion Criteria:

* Any psychotic disorder or current psychiatric symptoms requiring specific attention, including active symptoms of psychosis or suicidal/homicidal ideation
* Pregnant women
* Inability to give informed consent
* Traumatic brain injury or loss of consciousness
Audio and Video Brochures for Increasing Colorectal Cancer Screening Among Adults Living in Appalachia

This clinical trial compares audio brochures and video brochures to usual care for increasing colorectal cancer (CRC) screening among adults living in Appalachia. Adults living in rural Appalachia experience increased rates of CRC, possibly due to the unique barriers to screening this population faces, such as lower socioeconomic status, limited health literacy, and less access to healthcare. The fecal immunochemical test (FIT) is a common CRC screening technique which allows individuals to complete the test at home and mail the kit back. A limitation of the current process for FIT screening outreach is that the instruction materials are heavy in text and not appropriate for individuals with limited health literacy. The audio and video brochures used in this clinical trial are instruction materials that have been specially designed to be appropriate for individuals of all health literacy levels. Providing these audio and video brochures with the FIT kits may increase CRC screening among adults living in Appalachia, compared to usual care.

PRIMARY OBJECTIVE:

I. Conduct a pilot study of the two developed mail-based FIT outreach interventions versus (vs.) mailed usual care materials to establish acceptability and obtain preliminary efficacy data on increasing CRC screening.

OUTLINE: Participants are randomized to 1 of 3 arms.

ARM I: Participants receive the FIT kit and usual care on study.

ARM II: Participants receive the FIT kit with an audio brochure, disposable gloves and stool collection device, and scheduled reminder on study.

ARM III: Participants receive the FIT kit with a video brochure, disposable gloves and stool collection device, and scheduled reminder on study.

Eligibility Criteria:
Inclusion Criteria:

* Mid-life men and women (50-64 years old)
* Live in Appalachia
* Had a medical visit in the past two years
* Are at average-risk for CRC (no history of CRC, polyps, inflammatory bowel disease, family history of CRC or hereditary CRC syndromes)
* Are not within CRC screening guidelines (no fecal occult blood test/FIT in the past year; flexible sigmoidoscopy in past five years; colonoscopy in past ten years)
Effect of Vestibular Stimulation on Motor Proficiency and Balance Among Children With Down Syndrome

This was a randomized controlled trial study where there the total participants were 22and these participants were randomly selected and then distributed in to two groups all participants were selected according to the inclusion exclusion criteria of the study and then they were randomly distributed in two groups named as group A and group B both of the contain equal number of participants which are randomly distributed in groups each group contain 11 participants .Group A received the vestibular stimulation by swing in different positions supine, prone and with or without support in each position for 10minnts 3 times a week for 10 weeks along with general strengthening exercises of upper and lower limb and group B will receive general strengthening exercises of whole body for same time period. Data will be then analyzed by using SPSS windows version 25

This was a randomized controlled trial study where there the total participants were 22and these participants were randomly selected and then distributed in to two groups all participants were selected according to the inclusion exclusion criteria of the study and then they were randomly distributed in two groups named as group A and group B both of the contain equal number of participants which are randomly distributed in groups each group contain 11 participants .Group A received the vestibular stimulation by swing in different positions supine, prone and with or without support in each position for 10minnts 3 times a week for 10 weeks along with general strengthening exercises of upper and lower limb and group B will receive general strengthening exercises of whole body for same time period.

Eligibility Criteria:
Inclusion Criteria:• Down syndrome

* Age 6 to 11 years
* Having no other medical history (6)

Exclusion Criteria:

* • Visual impairment

  * Patient with hearing impairment
  * Patient with poor cognition (6, 8)
Prospective Cohort Study of a Population at Risk of Psychotic Transition

In psychiatry, insight is the patient's awareness of his or her disorder or symptom. Lack of insight also seems to be associated with the presence of anxiety-depressive symptoms.

There are several forms of insight:

* clinical" insight, which is the perception of suffering from a given pathology or symptoms
* cognitive insight (CI), which is the ability to analyse or judge one's own thoughts, beliefs and judgements
* and the insight of cognitive disorders or the subjective perception of the cognitive alterations (or cognitive symptoms) presented. In this study, the investigators will refer to this dimension as 'subjective cognitive complaint' (SCP), in order to differentiate it from cognitive insight, the name of which may lead to confusion.

In schizophrenic disorders, there is a positive correlation between the subjective cognitive complaint SCC, and certain alterations in the neurocognitive assessment, including the attentional dimension. There are scales for collecting SCC in psychotic disorders, such as the SSTICS. To date, there is no scale validated specifically for the UHR population. Thus, the scales used (STICSS, SCoRS, etc.) are validated in populations presenting a characterised psychotic state. Objective impairment is measured during a neurocognitive assessment carried out by a specialised professional: a clinical psychologist specialised in neuropsychology. The cognitive performance of UHR patients is impaired, particularly in terms of cognitive flexibility and self-perception of cognitive disorders, and there may be a discrepancy between the complaint, the objective disorders and their identification as "disorders" by the patient.

Despite this discrepancy, to the investigators knowledge no study to date has investigated a possible link between SCC and psychotic transition in this population. Thus, it is not known whether social class may be a factor in exposure to transition, or whether there is a link at all between social class and risk of transition. The aim of this study is to determine psychotic transition in UHR in a 30 months follow-up, and to determine whether there is a link between SCC and transition.


Eligibility Criteria:
Inclusion Criteria:

* Male or female ;
* Be aged between 15 and 30 ;
* Being assessed by the eDIP (early intervention team "équipe de détection et d'intervention précoce") ;
* Sufficient level of French to understand and express yourself orally and in writing;
* For adults:

Patients who have received informed information about the study and who have signed a consent to participate in the study;

- For minors: Patient who has received informed information about the study and who has signed, as well as the holders of parental authority the minor's consent to participate in the study.

Exclusion Criteria:

* Have already presented a First Psychotic Episode;
* Previous diagnosis of schizophrenia, psychotic disorder or bipolar disorder;
* Being on antipsychotic treatment at the time of inclusion ;
* Known intellectual disability ;
* Pregnant or breast-feeding woman;
* Minors and adults under legal protection.
Evaluation of Bacterial and Fungal Contamination During Propofol Continuous Infusion

The purpose of this study is to verify the existence of bacterial and/or fungal contamination during different technics of propofol with or without EDTA continuous infusion in patients undergoing general anesthesia.


Eligibility Criteria:
Inclusion Criteria:

* Age eighteen years old or more
* ASA Physiological Status P1 ou P2
* Patients undergoing clean procedure under general anesthesia.

Exclusion Criteria:

* Patients under eighteen years old
* ASA Physiological Status P3, P4 or P5
* Current infectious process
Esophageal and Gastric Registry and Biorepository

The evaluation of the foregut, the esophagus and stomach, has come a long way over the past two decades, and continues to experience exciting discoveries in the clinical evaluation of foregut physiology. Assessing esophageal peristalsis has relied for the past several decades on High Resolution Manometry (HRM), however it has recently become known that even though HRM is an extremely effective tool, that there are certain subsets of patients in which additional information is required. Additionally, the assessment of esophageal reflux disease has relied on pH impedance for the last two decades. However, this procedure requires a catheter to be passed through a nostril and remain in place for at least 24 hours. Novel techniques, already FDA approved, including EndoFLIP for esophageal peristalsis and mucosal integrity (MI) for reflux disease, have emerged as time-of-endoscopy assessments. Both involve the placement of a balloon through the scope at time of upper endoscopy (standard first line assessment for both dysphagia and reflux symptoms) and are quick and pose little-to-no additional risk or discomfort for patients. However, data regarding normal esophageal parameters are poorly defined for both EndoFLIP and MI. Additionally, EndoFLIP has increasingly been used to assess the pylorus, and scarce data exists there regarding how a tool originally envisioned for esophageal assessment can be used more distally in the GI tract.

We will recruit healthy, asymptomatic volunteers to undergo testing with MI and FLIP (esophageal and pyloric). The data obtained will help establish the benchmark from which assessments can be made in patients.


Eligibility Criteria:
Inclusion Criteria:

* Age 18-85
* No prior surgical history
* Asymptomatic according to gastroesophageal and gastric questionnaires
* Not currently taking any medications that affect acid secretion or gut motility
* No history of malignancy
* No mental health issues precluding informed consent
* No smoking history
* No excessive or daily alcohol use
* BMI \< 30
* No known hiatus hernia
* No known medical illness (autoimmune, neurological) that could be associated with altered esophageal or gastric function
* Not allergic to fentanyl or versed
* No history of eating disorder
* No history of autoimmune disorders

Exclusion Criteria:

* Minors
* Surgeries involving the GI tract
* Medication use affecting acid secretion or gut motility
* Personal history of malignancy
* Mental health issues precluding informed consent
* Symptoms on standard clinical questionnaires
* Pregnant - the effect that pregnancy has on esophageal and gastric motility is not well defined, but we will need to eliminate this as a confounding factor
* Nursing women - although the investigations are FDA approved and part of standard clinic practices, they are time consuming and involve medication administration that might affect the ability of a mother to nurse
Registry (Prospective Cohort) for Heart Failure in Korea (KorAHF)

KorAHF is a multi-center registry (prospective cohort) for acute decompensated heart failure patients in Korea.

The aim of this registry is to analyze several causes affecting prognosis and survival and to develop new strategies for managing acute decompensated heart failure.


Eligibility Criteria:
Inclusion Criteria:

All consecutive hospitalized adult patients who have 1 and (2 and/or 3)

1. Symptom and/or sign of heart failure
2. Lung congestion
3. Objective finding of LV systolic dysfunction (LVEF), or structural heart disease

Exclusion Criteria:

* N.C.
Research on the Complex Scientific Mechanisms Underlying Exercise and Health: Construction and Application of a Mechanistic Model and Public Database（CISS）

Dear Sugar Lovers:

Greetings!

In order to improve the knowledge of chronic disease prevention and control of sugar users and promote health, the investigators plan to organise participants to participate in the Diabetes Exercise Intervention, Science Promotion and Publicity of Chronic Disease Prevention and Control Knowledge Survey, and the investigators hope to get participant's support and cooperation. Please read the following procedure carefully:

1. Exercise intervention: we 2023 late November to start the intervention course.
2. Blood test 2 times (fasting insulin, glycated haemoglobin, total cholesterol, triglyceride, HDL, LDL, fasting blood glucose, tumour necrosis factor, etc., finger blood glucose.

   All the above tests are free of charge
3. popularisation: we will join hands with the community health service centre of Liaojin Village to conduct at least 3 talks on the prevention and control of diabetes.

   The investigators will cooperate with the community health service centre of Lijincun to carry out at least 3 times of knowledge dissemination on diabetes prevention and control.
4. Chronic disease knowledge prevention and control survey: For your physical and mental health development, the follow-up questionnaire is a knowledge survey questionnaire.

Please read the questions carefully. Participants privacy and confidentiality will be strictly protected and will not be disclosed to any unauthorised person.

If participants agree to participate in the programme, please confirm the following information and sign!

1. Co-operation and co-ordination: the investigators promise to participate in the whole project and maintain good communication and co-operation.

   The investigators will keep abreast of and respond to notices, feedback and suggestions, and provide the necessary support and co-operation.
2. Informed Consent: The investigators understand and agree to participate in the project.


Eligibility Criteria:
Inclusion Criteria:

* Patients with T2DM and diagnosed 6 months or more ago
* Meet the criteria of the dawn phenomenon
* Willing to sign the informed consent form
* Voluntarily accept the relevant examinations and tests
* No change in sleep habits in the past 2 weeks

Exclusion Criteria:

* T1DM, special type of diabetes, secondary diabetes, gestational diabetes;
* Nocturnal hypoglycemic reactions due to oral hypoglycemic agents or insulin use
* Patients with serious complications
The "PC-LIGHT" Study

Fatigue due to cancer and its treatment (for example, radiation therapy) can interfere with quality of life and can linger long after treatment has ended, yet research examining preventative approaches has produced limited clinical benefit. The proposed study will provide information about systematic light exposure for the prevention of fatigue in prostate cancer patients undergoing radiation therapy and will investigate how it works. This study would facilitate the development of this potential preventative treatment, giving health care providers and cancer survivors a much-needed tool to help with cancer-related fatigue.


Eligibility Criteria:
Inclusion Criteria:

* Have been diagnosed with clinical localized prostate cancer,
* Are about to begin external beam radiation therapy (RT) for prostate cancer,
* Are 18 years of age or older,
* Are able to speak or read English,
* Have internet access.

Exclusion Criteria:

* History of light therapy use (e.g. systematic light exposure),
* Active infection
* History of chronic fatigue disorders
* Confounding underlying medical illnesses such as significant pre-existing anemia (Hb\<10 gm/dl)
* Diagnosed or suspected psychiatric or medical condition that might contribute to fatigue (other than those caused by the cancer or its treatment)
* Hypothyroidism or documented history of hypothyroidism on thyroid replacement hormone within \<3 months of initiating RT
* History of bipolar disorder or mania
* History of seasonal affective disorder
* Diagnosed sleep apnea, restless legs, or other sleep disorders (not including insomnia) known to affect fatigue
* Use of photosensitizing medication
* Plans to travel across more than 2 time zones during the study
* Shift worker
* Adults unable to consent, individuals who are not yet adults, pregnant women, and prisoners will be excluded from the study
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

This is an open-label trial to estimate the concentrations of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma (HL) or relapsed/refractory systemic anaplastic large cell lymphoma (sALCL) participants treated with either brentuximab vedotin or brentuximab vedotin + rifampicin.


Eligibility Criteria:
Inclusion Criteria:

* Male or female participants between 18 years and 75 years old, with relapsed or refractory HL or relapsed or refractory sALCL who have previously received at least 1 multiagent chemotherapy
* Measurable disease
* An Eastern Cooperative Oncology Group (ECOG) performance of 0 or 1
* Female participants who are postmenopausal for at least 1 year before the screening visit, surgically sterile, or agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 30 days after the last dose of study drug, or agree to practice true abstinence
* Male participants who agree to practice effective barrier contraception during the entire study treatment period through 6 months after the last dose of study drug or agree to practice true abstinence
* Clinical laboratory values as specified in the study protocol

Exclusion Criteria:

* Participants for whom rifampicin is contraindicated
* Previously received an allogeneic transplant.
* Participants with current diagnosis of primary cutaneous anaplastic large cell lymphoma (ALCL) (participants whose ALCL has transformed to sALCL are eligible).
* Known cerebral/meningeal disease including signs or symptoms of progressive multifocal leukoencephalopathy (PML)
* Female participants who are lactating and breastfeeding or pregnant
* Known human immunodeficiency virus (HIV) positive,
* Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection
Psychosocial Support for Acute Hospital Pain and Distress

The purpose of this randomized study is to determine the impact of three different types of psychosocial support delivered by social workers to patients reporting uncontrolled pain during a hospital stay. This study will examine the differential effects of brief mindfulness training, therapeutic suggestion, and psychoeducation for patients reporting uncontrolled pain.


Eligibility Criteria:
Inclusion Criteria:

* English-speaking males or females 18 or older within the University of Utah Hospital system reporting "intolerable pain" or "inadequate pain control" on the Clinically Aligned Pain Assessment Tool (CAPA; Donaldson \& Chapman, 2013).

Exclusion Criteria:

* Altered mental status due to delirium, psychosis, or pharmacological sedation as determined by clinical assessment.